 | Up a level |
Plaimauer, B; Kremer Hovinga, J A; Juno, C; Wolfsegger, M J; Skalicky, S; Schmidt, M; Grillberger, L; Hasslacher, M; Knöbl, P; Ehrlich, H; Scheiflinger, F (2011). Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies. Journal of thrombosis and haemostasis, 9(5), pp. 936-44. Oxford: Wiley-Blackwell 10.1111/j.1538-7836.2011.04224.x
Ferrari, S; Mudde, G C; Rieger, M; Veyradier, A; Kremer Hovinga, J A; Scheiflinger, F (2009). IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura. Journal of thrombosis and haemostasis, 7(10), pp. 1703-10. Oxford: Wiley-Blackwell 10.1111/j.1538-7836.2009.03568.x
Pos, W; Luken, B M; Hovinga, J A Kremer; Turenhout, E A M; Scheiflinger, F; Dong, J-F; Fijnheer, R; Voorberg, J (2009). VH1-69 germline encoded antibodies directed towards ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. Journal of thrombosis and haemostasis, 7(3), pp. 421-8. Oxford: Wiley-Blackwell 10.1111/j.1538-7836.2008.03250.x
